Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

SHA:688621 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	1,058	1,222	1,078	932.12	676.61	493.65
Revenue Growth	-4.32%	13.33%	15.70%	37.76%	37.06%	42.12%
Gross Profit Gross Profit Growth	566.31	661.45	541.14	528.35	375.46	263.68
Operating Income Operating Income Growth	61.95	209.23	176.32	193.46	156.14	119.97
Net Income Net Income Growth	49.63	203.87	177.41	184.76	156.47	105.66
Earnings Per Share EPS Growth	0.45	1.86	1.58	1.65	1.40	1.08
EPS Growth	-68.32%	17.72%	-4.24%	17.86%	29.80%	24.80%

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Pharmacy Research Services Pharmacy Research Services Growth	338.48	558.68	568.6	441.9
Clinical Trials and Bioanalytical Services Clinical Trials and Bioanalytical Services Growth	522.56	511.65	362.39	234.5
Innovative Drugs and Improved New Drugs Innovative Drugs and Improved New Drugs Growth	248.36	-	-	-
Intellectual Property Licensing Intellectual Property Licensing Growth	100	-	-	-
Equity Sharing Equity Sharing Growth	10.94	6.53	-	-
Total Total Growth	1,220	1,077	930.98	676.39

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	504.94	617.17	615.56	720.93	622.04	647.85
Total Debt Total Debt Growth	682.7	613.71	455.79	446.65	257.55	206.71
Net Cash (Debt) Net Cash Growth	-177.76	3.45	159.77	274.28	364.48	441.14
Net Cash Growth	-	-97.84%	-41.75%	-24.75%	-17.38%	414.12%
Net Cash Per Share Net Cash Per Share Growth	-1.62	0.03	1.42	2.45	3.26	4.50

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-42.46	93.21	32.02	92.86	103.96	88.25
Capital Expenditures CapEx Growth	-43.07	-42.43	-30.48	-72.96	-103.87	-84.96
Free Cash Flow Free Cash Flow Growth	-85.53	50.78	1.54	19.9	0.09	3.29
Free Cash Flow Growth	-	3206.74%	-92.28%	21552.67%	-97.21%	-90.84%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	53.52%	54.12%	50.18%	56.68%	55.49%	53.41%
Operating Margin	5.85%	17.12%	16.35%	20.76%	23.08%	24.30%
Pretax Margin	2.26%	17.08%	16.32%	20.75%	25.00%	24.73%
Profit Margin	4.69%	16.68%	16.45%	19.82%	23.13%	21.40%
FCF Margin	-8.08%	4.15%	0.14%	2.14%	0.01%	0.67%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 10, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	0.187	0.187	0.163	0.165	0.429	0.189
Dividend Per Share Growth	-42.99%	14.72%	-1.21%	-61.50%	126.41%	-
Dividend Yield	0.26%	0.30%	0.43%	0.24%	0.60%	0.22%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 10, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	152.98	33.31	23.80	42.28	52.35	92.07
Forward PE	-	30.32	12.29	24.18	41.58	79.34
P/FCF Ratio	-	133.74	2749.41	392.53	89126.79	2953.42
PS Ratio	7.13	5.56	3.92	8.38	12.11	19.71

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error